Clinical Trial Update: BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing branched-chain amino acids to rifaximin for secondary prophylaxis of hepatic encephalopathy in patients with cirrhosis is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Decompensated Cirrhosis
• Hepatic Encephalopathy
• Minimal Hepatic Encephalopathy

Drugs mentioned

• Rifaximin (rifaximin)
• branched-chain amino acids (branched-chain amino acids)

Snippet

Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh | Conditions: Hepatic Encephalopathy, Decompensated Cirrhosis | Phase 4 | Status: RECRUITING